Anti-Human CD71 (Clone T56/14) – Purified in vivo PLATINUM™ Functional Grade

The monoclonal antibody clone T56/14 is most commonly used in vivo in mice for research involving human xenograft tumor models, where human cancer cells are implanted into immunocompromised mice. T56/14 specifically targets human CD71 (transferrin receptor 1) and does not cross-react with the mouse homolog, allowing for selective detection or targeting of human cells within a mouse host.

Key in vivo applications in mice include:

• Detection and quantitation of human cells: T56/14 is used to distinguish and monitor the presence of human tumor cells during and after xenograft establishment because it binds specifically to human CD71, which is highly expressed on proliferating and malignant human cells.
• Studies of targeted therapy: It is sometimes used to evaluate CAR-T therapies, antibody-drug conjugates, or other modalities targeting human CD71, especially to assess efficacy and potential toxicity in humanized or xenograft models (e.g., liver-humanized mouse models mentioned as a use case for evaluating therapeutic safety when targeting human antigens in vivo).
• Cell isolation and tracking: Since T56/14 can be used in flow cytometry and immunohistochemistry, it is applied to track or sort human cells from mouse tissues post-engraftment.
• Immunohistochemistry and immunoprecipitation: T56/14 is validated for these techniques, allowing researchers to localize or pull down human CD71-expressing cells in tissue sections or lysates from mouse xenograft experiments.

T56/14 is not typically used to deplete or therapeutically target endogenous mouse cells, as it does not react with mouse CD71; for that purpose, other clones are used (such as 8D3 for anti-mouse CD71).

Summary table: Applications of T56/14 in mice

T56/14 is highly specialized for distinguishing human cells in in vivo mouse models, making it a critical tool in preclinical human cancer and immunotherapy research.

Based on the available information, when CD71 (T56/14 antibody) is used in research, it is sometimes assessed alongside other markers in broader immunophenotyping panels, particularly when studying erythroid differentiation. The proteins commonly evaluated in tandem with CD71 include:

CD235a (Glycophorin A) and CD36 are mentioned as markers that are less directly related but sometimes assessed together with CD71 (T56/14) when dissecting erythroid differentiation pathways. This makes biological sense given that CD71 is expressed on erythroid progenitors and plays a role in iron uptake, which is essential for hemoglobin synthesis during red blood cell development.

The T56/14 clone itself recognizes human CD71 (transferrin receptor), which is expressed on proliferating cells, activated lymphocytes, monocytes, macrophages, erythroid progenitors, and brain endothelium. Given these expression patterns, researchers studying lymphocyte activation or cellular proliferation may incorporate CD71 alongside other activation or proliferation markers in their experimental panels.

However, the search results do not provide extensive information about other specific antibodies frequently co-used with T56/14 in published literature. The primary context mentioned is the erythroid differentiation setting where CD235a and CD36 serve as complementary markers.

Scientific literature citations of clone T56/14 primarily reference it as a monoclonal antibody against human CD71 (transferrin receptor, TfR1), utilized for flow cytometry and immunological studies, but key experimental findings specific to the clone itself are limited.

Key findings and usages include:

• Application in flow cytometry: The T56/14 clone is widely employed to detect CD71 expression on cells, including in assays to analyze hematopoietic and immune cell populations in both research and clinical diagnostics. For example, it has been used in standardized flow cytometric assays to diagnose paroxysmal nocturnal hemoglobinuria by identifying loss or abnormal expression of glycosylphosphatidylinositol-anchored proteins like CD71.
• Reactivity: It is a mouse IgG1 isotype monoclonal antibody specific for human CD71, showing strong reactivity across most proliferating cells (activated lymphocytes, monocytes, macrophages, erythroid progenitors) as well as brain endothelium.
• Research on B cell and erythroid populations: Studies have employed T56/14 to characterize novel B cell subpopulations and to analyze erythroid cell surface markers in both healthy and disease states.
• No unique mechanistic studies linked to T56/14: There are no major scientific claims, structural insights, or therapeutic findings attributed uniquely to clone T56/14 apart from its demonstrated specificity and broad use as a flow cytometry reagent.

Additional context:

• It does not cross-react with porcine T cells, and its inability to bind was specifically noted in the context of evaluating T cell markers in pigs, highlighting its species specificity.
• The antibody is available from several commercial suppliers in various conjugations suitable for immunophenotyping.

In summary: Clone T56/14 is a validated and routinely used tool antibody for detecting human CD71 in flow cytometry and immunophenotyping. Its core scientific impact derives from facilitating studies of iron metabolism, hematology, and immune cell proliferation, but it is not itself the subject of notable unique findings in scientific literature to date.

Dosing regimens for clone T56/14 (anti-human CD71 antibody) across different mouse models are not explicitly described in available literature or product documentation. Researchers are advised to empirically determine the optimal working dilution and dose for their specific mouse model and experimental context.

Essential context and supporting details:

• Clone T56/14 is a monoclonal antibody targeting human CD71, used in vivo in mouse studies; however, the recommended dose, schedule, and adjustments for varying mouse models (such as differing strains, disease states, or experimental aims) are not published by suppliers or in peer-reviewed articles.
• Product guidelines indicate high purity and low endotoxin levels, and recommend storage best practices, but do not provide standardized dosing information.
• The dosing of other monoclonal antibodies in mouse models, such as those targeting immune checkpoints, usually ranges from 100–500 µg per mouse given via intraperitoneal injection every 3–4 days, but these are guidelines for unrelated clones (not T56/14).

Additional relevant information:

• For antibodies without published dosing regimens, each investigator should titrate and validate the dose and schedule according to experimental requirements, using lot-specific datasheets or pilot studies to optimize efficacy and minimize side effects.
• Mouse model variables (strain, body weight, target antigen expression, and disease state) can influence the effective dose.
• If no dosing recommendations are available, researchers often begin with a range (e.g., 100–500 µg/mouse i.p.) based on analogous antibodies, adjusting for their specific application and monitoring for efficacy and toxicity.

In summary, dosing regimens of clone T56/14 in mouse models are not standardized in publicly available documents; experiment-specific optimization by the investigator is necessary.